Results 71 to 80 of about 8,127 (167)

Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country [PDF]

Hikmat Abdel-Razeq,1,2 Baha Sharaf,1 Suhaib Khater,1 Huda Jafar Baidoun,2 Hira Bani Hani,1 Ayat Taqash,3 Osama El Khatib,1 Sarah Edaily,1 Mahmoud Abunasser,1 Faris Tamimi,1 Yosra Nabeel Al-Masri,1 Tamer Moh’d Waleed Al-Batsh,1 Anas Zayed,1 Tala Ghatasheh,
Baidoun HJ, Ghatasheh T, Edaily S, Abdel-Razeq H, Khater S, Al-Batsh TMW, Taqash A, Sharaf B, Tamimi F, Abunasser M, El Khatib O, Bani Hani H, Zayed A, Radaideh T, Al-Masri YN   +14 more
core  

Ribociclib-induced autoimmune-like hepatitis: a case report

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer represents the most prevalent subtype of breast cancer.
BALABAN, HATİCE YASEMİN, SÖKMENSÜER, CENK, ŞAHİN, TAHA KORAY, AKSOY, SERCAN, KAVGACI, GÖZDE   +4 more
core   +1 more source

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain

, 2018
Elena Galve-Calvo,1 Eva González-Haba,2 Joana Gostkorzewicz,3 Irene Martínez,4 Alejandro Pérez-Mitru4 1Medical Oncology Service, Basurto University Hospital, Bilbao, Spain; 2Pharmacy Department, Hospital Universitario Gregorio Mara ...
Gostkorzewicz J, Galve-Calvo E, Pérez-Mitru A, González-Haba E, Martínez I   +4 more
core  

Abstract P1-14-05: Ribociclib dose recommendations for potential pharmacokinetic drug interaction and in special patient populations with organ impairment

, 2018
Background: Ribociclib (Kisqali®) is a CDK4/6 inhibitor, recently approved in the U.S. as a first line therapy for HR+/HER2- advanced breast cancer (ABC) in combination with an aromatase inhibitor.
TS Samant, S Yang, F Huth, M Elmeliegy, M Laisney, M Quinlan, M Mueller-Zsigmondy, AM Abdelhady, A Chakraborty, X Liu, K-I Umehara, Y Lu, C Germa   +12 more
core   +1 more source

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Cancer Management and Research, 2020
Jiangping Yang,1,* Jiaqi Han,1,* Maolang Tian,1 Kun Tian,2 Wenjun Liao,1 Xi Yan3,4 1Department of Head and Neck Oncology and Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University ...
Yang J, Han J, Tian M, Tian K, Liao W, Yan X   +5 more
doaj  

Ribociclib may potentiate rosuvastatin effect in causing late onset rhabdomyolysis

, 2023
A woman in her 50s with metastatic hormone receptor positive breast cancer developed rhabdomyolysis and subsequent acute kidney injury while on a combination of ribociclib and rosuvastatin therapy.
T Hayes (12372037), SW Teo (22424203), James Gome (13071618)   +2 more
core  

Combining ribociclib with cytotoxic drugs did not increase cytotoxicity.

, 2019
(A) Table of average IC50 of three independent IC50 determinations of indicated cytotoxic drugs in indicated cell lines. (B) Different dosing schedules of combinations of ribociclib and cytotoxic drugs.
Dan Jin (322308), Nguyen Tran (147973), Nagheme Thomas (7485719), David D. Tran (7485722)   +3 more
core   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Overall survival with ribociclib plus endocrine therapy in breast cancer

, 2019
BackgroundAn earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in ...
Chakravartty, Arunava, Lu, Yen-Shen, Chow, Louis, Hurvitz, Sara, Lee, Keun-Seok, Franke, Fabio, Rodriguez-Lorenc, Karen, Jung, Kyung-Hae, Harbeck, Nadia, Tripathy, Debu, Gounaris, Ioannis, Campos-Gomez, Saul, Taran, Tetiana, Bardia, Aditya, Colleoni, Marco, Hughes, Gareth, Villanueva-Vazquez, Rafael, Im, Seock-Ah, Sohn, Joohyuk   +18 more
core   +1 more source

Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)

npj Breast Cancer
Optimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib dosing schedules.
Laura M. Spring, Lauren Scarpetti, Arielle J. Medford, Andrzej Niemierko, Amy Comander, Therese Mulvey, Lowell Schnipper, Steven J. Isakoff, Beverly Moy, Seth A. Wander, Jennifer Shin, Zanta Ephrem, Anneke R. Laposta, Elyssa Denault, Elizabeth Abraham, Gayle Calistro, Ekaterina Kalashnikova, Angel Rodriguez, Minetta C. Liu, Alexey Aleshin, Jeffrey Peppercorn, Leif W. Ellisen, Aditya Bardia   +22 more
doaj   +1 more source